Drug intelligence / Profile preview

METI-101

Development stage: Phase 2
Lead developer: MetiMedi Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems

Overview

METI-101 is a metabolism modulator and 'anticancer booster' developed by MetiMedi Pharmaceuticals. It is based on a novel hydroxyapatite (HA) material designated as MEDI-25. The drug is designed to enhance the efficacy of existing cancer treatments by facilitating effective calcium delivery to target tissues, bypassing normal homeostatic mechanisms. It is currently being investigated in Phase 1 clinical trials for refractory metastatic colorectal cancer and has potential applications in other inflammatory conditions like periodontitis.

Other names: Anticancer Booster

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on METI-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METI-101.